Geode Capital Management LLC Raises Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)

Geode Capital Management LLC raised its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 37.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 879,468 shares of the biotechnology company's stock after acquiring an additional 241,279 shares during the period. Geode Capital Management LLC owned approximately 1.93% of Capricor Therapeutics worth $12,139,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock worth $31,420,000 after purchasing an additional 700,243 shares during the last quarter. Black Diamond Financial LLC purchased a new position in Capricor Therapeutics during the 4th quarter valued at approximately $3,833,000. State Street Corp increased its stake in Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after acquiring an additional 111,291 shares during the last quarter. Swiss National Bank purchased a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $930,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Capricor Therapeutics by 419.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after acquiring an additional 45,381 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CAPR shares. HC Wainwright restated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald restated an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $34.50.

Capricor Therapeutics Price Performance

Shares of CAPR traded up $0.13 during midday trading on Thursday, hitting $13.28. The stock had a trading volume of 1,845,497 shares, compared to its average volume of 1,494,047. The stock's 50 day moving average is $12.13 and its 200 day moving average is $14.90. The firm has a market cap of $606.59 million, a PE ratio of -12.53 and a beta of 4.65. Capricor Therapeutics Inc has a 1 year low of $3.52 and a 1 year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. As a group, equities research analysts expect that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.